Last reviewed · How we verify
Emergency Department Initiated Oral Naltrexone
Emergency Department Initiated Oral Naltrexone is a Small molecule drug developed by Icahn School of Medicine at Mount Sinai. It is currently in Phase 1 development.
At a glance
| Generic name | Emergency Department Initiated Oral Naltrexone |
|---|---|
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Emergency Department Initiated Oral Naltrexone CI brief — competitive landscape report
- Emergency Department Initiated Oral Naltrexone updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI
Frequently asked questions about Emergency Department Initiated Oral Naltrexone
What is Emergency Department Initiated Oral Naltrexone?
Emergency Department Initiated Oral Naltrexone is a Small molecule drug developed by Icahn School of Medicine at Mount Sinai.
Who makes Emergency Department Initiated Oral Naltrexone?
Emergency Department Initiated Oral Naltrexone is developed by Icahn School of Medicine at Mount Sinai (see full Icahn School of Medicine at Mount Sinai pipeline at /company/icahn-school-of-medicine-at-mount-sinai).
What development phase is Emergency Department Initiated Oral Naltrexone in?
Emergency Department Initiated Oral Naltrexone is in Phase 1.